Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    AN2 Therapeutics Inc.

    NASDAQ: ANTX · Real-Time Price · USD
    1.14
    0.06 (5.56%)
    At close: Jun 17, 2025, 1:51 PM

    AN2 Therapeutics Statistics

    Share Statistics

    AN2 Therapeutics has 30.18M shares outstanding. The number of shares has increased by 0.9% in one year.

    Shares Outstanding

    n/a
    		 30.18M

    Shares Change (YoY)

    n/a
    		 0.9%

    Shares Change (QoQ)

    n/a
    		 0.74%

    Owned by Institutions (%)

    n/a
    		 48.69%

    Shares Floating

    n/a
    		 19.88M

    Failed to Deliver (FTD) Shares

    n/a
    		 122

    FTD / Avg. Volume

    n/a
    		 0.08%

    Short Selling Information

    The latest short interest is 33.18K, so 0.11% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 33.18K

    Short % of Shares Out

    n/a
    		 0.11%

    Short % of Float

    n/a
    		 0.18%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.8 and the forward PE ratio is -0.8. AN2 Therapeutics's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -0.8

    Forward PE

    n/a
    		 -0.8

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.1

    PB Ratio

    n/a
    		 0.5

    P/FCF Ratio

    n/a
    		 -0.84

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for AN2 Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.43, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 8.43

    Quick Ratio

    n/a
    		 8.43

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,332,772.73

    Employee Count

    n/a
    		 22

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -46.86% in the last 52 weeks. The beta is -0.08, so AN2 Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.08

    52-Week Price Change

    n/a
    		 -46.86%

    50-Day Moving Average

    n/a
    		 1.2

    200-Day Moving Average

    n/a
    		 1.21

    Relative Strength Index (RSI)

    n/a
    		 40.53

    Average Volume (20 Days)

    n/a
    		 160,223

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -54.55M

    Net Income

    n/a
    		 -51.32M

    EBITDA

    n/a
    		 -51.32M

    EBIT

    n/a
    		 -51.32M

    Earnings Per Share (EPS)

    n/a
    		 -1.72
    Full Income Statement

    Balance Sheet

    The company has 21.35M in cash and 0 in debt, giving a net cash position of 21.35M.

    Cash & Cash Equivalents

    n/a
    		 21.35M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -205.78M

    Total Assets

    n/a
    		 81.34M

    Working Capital

    n/a
    		 61.55M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -49.26M and capital expenditures 0, giving a free cash flow of -49.26M.

    Operating Cash Flow

    n/a
    		 -49.26M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -49.26M

    FCF Per Share

    n/a
    		 -1.65
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ANTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ANTX is $3.5, which is 218.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $3.5

    Price Target Difference

    n/a
    		 218.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.25

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist